<DOC>
	<DOCNO>NCT01854918</DOCNO>
	<brief_summary>This study contribute evaluation long-term safety , tolerability efficacy evolocumab ( AMG 145 ) subject hyperlipidemia subject mixed dyslipidemia .</brief_summary>
	<brief_title>Open Label Study Long Term Evaluation Against LDL-C Trial-2</brief_title>
	<detailed_description />
	<mesh_term>Dyslipidemias</mesh_term>
	<mesh_term>Hyperlipidemias</mesh_term>
	<criteria>Complete qualify evolocumab ( AMG 145 ) parent study Experienced treatmentrelated serious adverse event lead IP discontinuation parent study Have unstable medical condition , judgment investigator Known sensitivity product administer dose Currently enrol another investigational device drug study ( exclude evolocumab ( AMG 145 ) parent study ) , less 30 day since end another investigational device drug study ( ) , receive investigational agent ( )</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>85 Years</maximum_age>
	<verification_date>January 2017</verification_date>
	<keyword>High cholesterol</keyword>
	<keyword>Raised cholesterol</keyword>
	<keyword>Cholesterol</keyword>
	<keyword>Elevated Cholesterol</keyword>
</DOC>